Treating COVID-19 Paxlovid is Shown to be Effective

In a recent Report published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers described cases of coronavirus disease 2019 (COVID-19)–related hospitalizations and emergency department (ED) visits in five to 15 days following Paxlovid (Nirmatrelvir/ritonavir) treatment.

Nirmatrelvir/ritonavir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) inhibitor, is marketed under the brand name Paxlovid. It received emergency use authorization (EUA) from the Food and Drug Administration (FDA) in December 2021 for mild to moderate COVID-19 cases likely at risk for developing severe disease. There are some published reports of recurrence of SARS-CoV-2 infections after completion of the Paxlovid treatment. However, there is a lack of real-world evidence to show that early intervention with Paxlovid prevents the progression of mild and moderate COVID-19 cases to severity.

The study findings showed that the symptoms experienced by patients with recurrent SARS-CoV-2 infections after treatment with Paxlovid were milder than the symptoms experienced during the primary infection. Patients with reinfections following Paxlovid treatment were unlikely to get hospitalized or visit ED. Subsequently, less than 1% of patients treated with Paxlovid had to be hospitalized or visited ED due to COVID-19-related complications.

One likely explanation is that Paxlovid transiently suppresses SARS-CoV-2 replication before natural immunity completely clears the virus, thus, allowing for a short interval to observe a rebound-associated increase in loads of SARS-CoV-2. Moreover, studies have not adequately investigated the severity of the symptoms of SARS-CoV-2 reinfections. Recurrence of symptoms likely appears in some individuals regardless of treatment and vaccination status. The present study examined around 5,000 Paxlovid-treated COVID-19 patients. Thus, its findings could be reliably indicative that treatment- or immune-mediated responses, or a combination of both, could be effective in preventing hospitalization for most Paxlovid-treated patients.

It is also noteworthy that the rebound of COVID-19 symptoms after Paxlovid treatment might be related to other factors, such as treatment-resistant mutations. The researchers did not perform SARS-CoV-2 genome sequencing on samples collected from the study participants prior to and after the initiation of Paxlovid treatment. Therefore, they could not be 100% sure that the progression of the initial illness was COVID-19 reinfection. However, preliminary results from FDA research studies have indicated that SARS-CoV-2 reinfection in several individuals is unassociated with resistance mutations. To conclude, additional research could provide insights into the association between Paxlovid treatment and reduced risk for severe COVID-19, including studies with controls and precise COVID-19 severity indicators.

In detail: https://www.tridhascholars.org/press-release/treating-covid-19-paxlovid-is-shown-to-be-effective.php

Comments

Post a Comment

Popular posts from this blog

COVID- 19 Observation for Fully Vaccinated and Boosted Patients

The researchers concluded that booster doses provided protection against severe COVID-19 symptoms and also observed that the number of patients requiring   mechanical ventilation   and use of vasopressors, as well as in-hospital mortality, were lower in the FV&B cohorts as compared to the UV cohorts, despite a higher risk for in-hospital mortality in the FV&B cohort. When the researchers compared the FV&B patients who required ICU care to those who did not, it was observed that there may not have been enough time for the booster dose in these patients to be effective in preventing COVID-19 symptoms. Decreased in-hospital mortality was observed in FV&B patients compared to UV patients, even though the former group was older and had a higher rate of pre-existing ESRD, higher proportion of immunocompromised state, and a higher proportion of immunocompromised state risk of in-hospital death in the FV&B cohort. It was observed that even among elderly patients with signi
Read more

SARS-CoV-2 Infection and Nasopharyngeal Microbiota

C anadian researchers investigated how  severe acute respiratory syndrome coronavirus 2  (SARS-CoV-2) infection altered the microbiota composition of the host’s nasopharyngeal region. The risk and clinical outcomes of SARS-CoV-2 infection vary widely among individuals. However, the mechanisms underlying these differences in  coronavirus disease 2019  (COVID-19) progression and pathogenesis remain unclear. Studies have shown that the mucosal microbiome influences host toll-like receptor (TLR) expression, which is involved in virus detection. Studies have also shown the prevalence of bacterial co-infections in COVID-19 patients at 6.9%. Likewise, elevated nasal cytokines have been implicated in adverse clinical outcomes in influenza patients. Therefore, exploring upper respiratory tract microbiota compositional changes following SARS-CoV-2 infection could help evaluate its impact on  infection  severity. Overall, the study results presented a granular picture of the microbiota difference
Read more

TRIDHA Scholars : An Open Access Publisher

 HI... TRIDHA Scholars is an open access Publishing company of India and it publishes all kind of paper related to clinical and medical field of Science. We have around 10 running journals on the very kind of particular topic of Clinical Science. Here is the list of the journals below. 1. Journal of Clinical Cases and Report 2. International Journal of Clinical and Medical Informatics 3. Clinical Surgery Journal 4. Cancer Medicine Journal 5. Journal of Medicine and Biology 6. Clinical Practice and Investigation 7. Journal of Heart 8. Case Reports in Dental Science 9. Food Processing and Nutrional Science 10. International Journal of AAYUSH and Traditional Medicine (Official Journal of  SGM, Ayurveda Mahavidyalaya, Pusad, Pune, India ) So, we would like to share it and help us to contribute in scientific community by publishing their work on time. We assure the quality process and complete the peer review process without any fail. Web: https://www.tridhascholars.org/ Contact: contact.tr
Read more